Emerging Therapies and Management Strategies for Myelodysplastic Syndromes and Myeloid Malignancies

The Aplastic Anemia and MDS International Foundation
September 17, 2020

The Aplastic Anemia and MDS International Foundation invites you to participate in our ONS Bridge satellite symposium, Emerging Therapies and Management Strategies for MDS and Myeloid Malignancies on Thursday September 17^th at 5:00 pm. 

MDS is challenging to diagnose, but the evolving genomic and immunologic landscape of MDS has led to notable improvements in the accuracy and timing of MDS diagnosis, prognosis, and identification of possible targets for therapeutic intervention. New therapies have been approved this year and several novel agents and combination therapies are in development, so it is important that nurses and nurse practitioners are aware of the treatment options available for this patient population.

Topics will include:

• Latest developments in diagnosing and treating myeloid malignancies;
• Emerging treatment options for low-risk MDS, high-risk MDS, AML, and MDS/MPN overlap;
• Disease management for chronic anemia, side effects and treatment adherence;
• Psychosocial considerations and palliative care to improve the quality of life for this patient population.

Case studies will be used to illustrate treatment decision-making and therapeutic challenges.

Our outstanding faculty has extensive inpatient and outpatient experience with MDS patients and will provide up-to-date information and practical guidance

• Christina Cline, RN, BSN, CCRC, Senior Registered Nurse Manager,
  University of Florida, Gainesville, FL
• Allyson Price, MPAS, PA-C, Physician Assistant, Department of Leukemia,
  University of Texas MD Anderson Cancer Center, Houston, TX
• Kirsten Roblee, RN, BSN, OCN, Assistant Nurse Manager,
  The James Cancer Hospital and Solove Research Institute, Columbus, OH